Victory Capital Management Inc Denali Therapeutics Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

A detailed history of Victory Capital Management Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 39,900 shares of DNLI stock, worth $855,057. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,900

Previous 15,133 163.66%

Holding current value

$855,057

Previous $351,000 231.05%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$20.96 - $31.05 $519,116 - $769,015	24,767 Added 163.66%	39,900 $1.16 Million
Q2 2024 Aug 05, 2024	BUY	$14.96 - $23.22 $5,834 - $9,055	390 Added 2.65%	15,133 $351,000
Q1 2024 May 03, 2024	SELL	$15.83 - $23.35 $9,577 - $14,126	-605 Reduced 3.94%	14,743 $302,000
Q4 2023 Feb 05, 2024	BUY	$16.2 - $23.18 $52,925 - $75,729	3,267 Added 27.04%	15,348 $329,000
Q3 2023 Nov 06, 2023	BUY	$20.63 - $30.17 $12,996 - $19,007	630 Added 5.5%	12,081 $249,000
Q2 2023 Jul 27, 2023	SELL	$23.37 - $32.96 $6,239 - $8,800	-267 Reduced 2.28%	11,451 $337,000
Q1 2023 May 02, 2023	SELL	$21.91 - $32.67 $33,697 - $50,246	-1,538 Reduced 11.6%	11,718 $269,000
Q4 2022 Feb 10, 2023	BUY	$26.28 - $33.92 $3,153 - $4,070	120 Added 0.91%	13,256 $368,000
Q4 2022 Feb 09, 2023	BUY	$26.28 - $33.92 $39,709 - $51,253	1,511 Added 13.0%	13,136 $365,000
Q3 2022 Nov 02, 2022	BUY	$25.97 - $38.53 $19,269 - $28,589	742 Added 6.82%	11,625 $357,000
Q1 2022 May 04, 2022	SELL	$29.0 - $47.27 $34,742 - $56,629	-1,198 Reduced 9.92%	10,883 $259,000
Q4 2021 Feb 07, 2022	SELL	$42.59 - $55.02 $410,013 - $529,677	-9,627 Reduced 44.35%	12,081 $539,000
Q3 2021 Nov 02, 2021	SELL	$48.48 - $78.23 $989,622 - $1.6 Million	-20,413 Reduced 48.46%	21,708 $1.1 Million
Q2 2021 Aug 03, 2021	BUY	$50.3 - $78.44 $189,429 - $295,405	3,766 Added 9.82%	42,121 $3.3 Million
Q1 2021 May 04, 2021	BUY	$53.8 - $81.53 $1.06 Million - $1.61 Million	19,788 Added 106.58%	38,355 $2.19 Million
Q4 2020 Feb 01, 2021	BUY	$36.89 - $93.56 $224,992 - $570,622	6,099 Added 48.92%	18,567 $1.56 Million
Q3 2020 Nov 09, 2020	SELL	$23.13 - $38.84 $15,520 - $26,061	-671 Reduced 5.11%	12,468 $447,000
Q2 2020 Aug 07, 2020	SELL	$16.01 - $28.82 $7,748 - $13,948	-484 Reduced 3.55%	13,139 $318,000
Q1 2020 May 04, 2020	BUY	$14.2 - $27.98 $511 - $1,007	36 Added 0.26%	13,623 $239,000
Q4 2019 Feb 06, 2020	BUY	$14.4 - $19.99 $31,478 - $43,698	2,186 Added 19.17%	13,587 $237,000
Q4 2019 Feb 04, 2020	SELL	$14.4 - $19.99 $58,089 - $80,639	-4,034 Reduced 26.14%	11,401 $264,000
Q3 2019 Nov 12, 2019	BUY	$15.32 - $21.92 $236,464 - $338,335	15,435 New	15,435 $236,000

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account

Victory Capital Management Inc Denali Therapeutics Inc. Transaction History